About Pressure BioSciences (OTCMKTS:PBIO)
Pressure BioSciences, Inc. is focused on solving the problems inherent in biological sample preparation. The Company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, such as approximately 35,000 pounds per square inch (psi) or greater to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources. Its laboratory instrument, the Barocycler, and its consumables product line, which include its Pressure Used to Lyse Samples for Extraction (PULSE) tubes, and other processing tubes, and application specific kits, such as consumable products and reagents, together make up its PCT Sample Preparation System (PCT SPS). The Company is also the distributor for the Constant Systems cell disruption equipment, parts, and consumables.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Symbol: OTCMKTS:PBIO
- CUSIP: N/A
- Web: www.pressurebiosciences.com
Capitalization:- Market Cap: $4.84 million
- Outstanding Shares: 1,101,000
Average Prices:- 50 Day Moving Avg: $3.99
- 200 Day Moving Avg: $6.24
- 52 Week Range: $0.70 - $11.40
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -27.50
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.05 million
- Price / Sales: 2.36
- Book Value: ($11.90) per share
- Price / Book: -0.37
Profitability:- EBITDA: ($3,820,000.00)
- Net Margins: -190.47%
- Return on Assets: -547.67%
Debt:- Current Ratio: 0.14%
- Quick Ratio: 0.06%
Misc:- Average Volume: 3,370 shs.
- Beta: 1.67
- Short Ratio: 3
Frequently Asked Questions for Pressure BioSciences (OTCMKTS:PBIO)
What is Pressure BioSciences' stock symbol?
Pressure BioSciences trades on the OTCMKTS under the ticker symbol "PBIO."
How were Pressure BioSciences' earnings last quarter?
Pressure BioSciences Inc. (OTCMKTS:PBIO) released its quarterly earnings results on Wednesday, August, 16th. The company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.90) by $0.36. The company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.78 million. View Pressure BioSciences' Earnings History.
When will Pressure BioSciences make its next earnings announcement?
Who are some of Pressure BioSciences' key competitors?
Some companies that are related to Pressure BioSciences include Argos Therapeutics (ARGS), Relmada Therapeutics (RLMDD), Acura Pharmaceuticals (ACUR), ESSA Pharma (EPIX), Roka Bioscience (ROKA), Bio Blast Pharma (ORPN), Nivalis Therapeutics (ALPN), Dynatronics Corporation (DYNT), Avinger (AVGR), TearLab Corporation (TEAR), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Ritter Pharmaceuticals (RTTR), Strata Skin Sciences (SSKN), Prana Biotechnology Ltd (PRAN), NeuroMetrix (NURO), Dextera Surgical (DXTR) and Windtree Therapeutics (WINT).
Who are Pressure BioSciences' key executives?
Pressure BioSciences' management team includes the folowing people:
- Jeffery N. Peterson, Independent Chairman of the Board
- Richard T. Schumacher, President, Chief Executive Officer, Treasurer, Secretary, Clerk, Director
- Joseph L. Damasio Jr., Chief Financial Officer, Vice President - Finance
- Edmund Y. Ting Ph.D., Senior Vice President - Engineering
- Nathan P. Lawrence Ph.D., Vice President of Sales and Marketing
- Alexander V. Lazarev Ph.D., Vice President - Research & Development
- Michael S. Urdea, Director
- Vito J. Mangiardi, Independent Director
- Kevin A. Pollack, Independent Director
How do I buy Pressure BioSciences stock?
Shares of Pressure BioSciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pressure BioSciences' stock price today?
One share of Pressure BioSciences stock can currently be purchased for approximately $4.40.
MarketBeat Community Rating for Pressure BioSciences (OTCMKTS PBIO)MarketBeat's community ratings are surveys of what our community members think about Pressure BioSciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Pressure BioSciences (OTCMKTS:PBIO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Consensus Price Target History for Pressure BioSciences (OTCMKTS:PBIO)
Analysts' Ratings History for Pressure BioSciences (OTCMKTS:PBIO)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Pressure BioSciences (OTCMKTS:PBIO)Earnings History by Quarter for Pressure BioSciences (OTCMKTS PBIO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/15/2017 | | | | | | | | |
| 8/16/2017 | Q2 2017 | ($0.90) | ($0.54) | $0.78 million | $0.54 million | View | N/A |  |
| 5/16/2017 | Q1 2017 | | ($0.18) | | $0.55 million | View | N/A | |
| 8/17/2015 | | ($0.04) | ($0.09) | $0.58 million | $0.41 million | View | N/A | |
| 4/1/2015 | | ($0.07) | ($0.09) | $0.50 million | $0.29 million | View | N/A | |
| 11/17/2014 | | ($0.11) | ($0.07) | $0.46 million | $0.37 million | View | N/A | |
| 8/14/2014 | | ($0.11) | ($0.05) | $0.39 million | $0.31 million | View | N/A | |
| 5/15/2014 | | ($0.10) | ($0.25) | $0.34 million | $0.40 million | View | N/A | |
| 4/2/2014 | | ($0.07) | ($0.14) | | | View | N/A | |
| 8/15/2013 | Q2 2013 | ($0.06) | ($0.10) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Pressure BioSciences (OTCMKTS:PBIO)Current Year EPS Consensus Estimate: $-0.28 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS
Dividend History for Pressure BioSciences (OTCMKTS:PBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pressure BioSciences (OTCMKTS:PBIO)Insider Ownership Percentage: 20.80%
Insider Trades by Quarter for Pressure BioSciences (OTCMKTS:PBIO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/26/2014 | Richard T Schumacher | CEO | Buy | 13,200 | $0.30 | $3,960.00 | |
| 9/13/2013 | Richard T Schumacher | CEO | Buy | 2,500 | $0.31 | $775.00 | |
| 9/12/2013 | Richard T Schumacher | CEO | Buy | 20,500 | $0.30 | $6,150.00 | |
| 9/9/2013 | Richard T Schumacher | CEO | Buy | 15,500 | $0.28 | $4,340.00 | |
| 8/30/2013 | Michael S Urdea | Director | Buy | 50,000 | $0.29 | $14,500.00 | |
| 8/30/2013 | Richard T Schumacher | CEO | Buy | 10,000 | $0.29 | $2,900.00 | |
| 8/28/2013 | Richard T Schumacher | CEO | Buy | 15,000 | $0.28 | $4,200.00 | |
| 8/23/2013 | Richard T Schumacher | CEO | Buy | 20,000 | $0.27 | $5,400.00 | |
| 8/21/2013 | Kevin Pollack | Director | Buy | 10,000 | $0.28 | $2,800.00 | |
| 10/8/2012 | Clayton A Struve | Major Shareholder | Buy | 76,350 | $0.38 | $29,013.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Pressure BioSciences (OTCMKTS:PBIO)
Latest Headlines for Pressure BioSciences (OTCMKTS:PBIO)
| Source: |
|
| Date | Headline |
|---|
 | CEO Richard T. Schumacher Discusses Pressure BioScience’s New Sales Team and Novel Products that are Fueling its Progressive Upturn
finance.yahoo.com - October 11 at 6:24 AM |
| Pressure BioSciences' Penetration in European Biopharma and High Pressure Markets Continuing to Expand via Multiple Scientific Presentations in Germany, Poland, and Ireland
finance.yahoo.com - October 11 at 6:24 AM |
| Pressure BioSciences, Inc. to Present at the 2017 Disruptive Growth Company Showcase in New York City on September 27, 2017
finance.yahoo.com - October 3 at 3:16 AM |
| Pressure BioSciences, Inc. Issued First Two Patents on Widely-Applicable, High Pressure-Based Ultra Shear Technology ("UST")
finance.yahoo.com - October 3 at 3:16 AM |
| Pressure BioSciences' Next-Generation Barocycler 2320EXTREME Named a Finalist in the Prestigious 2017 R&D 100 Awards
finance.yahoo.com - September 19 at 6:20 AM |
| Pressure BioSciences, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 11, 2017
finance.yahoo.com - September 12 at 8:26 AM |
| Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 8:11 AM |
 | Pressure BioSciences Inc. (PBIO) Releases Quarterly Earnings Results, Beats Estimates By $0.33 EPS
www.americanbankingnews.com - August 16 at 10:50 AM |
| Pressure BioSciences, Inc. to Discuss Second Quarter 2017 Financial Results and Provide Business Update
finance.yahoo.com - August 16 at 6:38 AM |
| PRESSURE BIOSCIENCES INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 22 at 7:07 PM |
 | FinancialBuzz.com Innovation in the Sample Preparation Market
www.bizjournals.com - March 1 at 10:17 AM |
| PRESSURE BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - January 3 at 11:45 PM |
| Q3 2016 Pressure Biosciences Inc Earnings Release - Time Not Supplied
biz.yahoo.com - November 16 at 10:27 AM |
Pressure BioSciences (PBIO) Chart for Tuesday, October, 17, 2017
